FDA approves atezolizumab combinations for specified Stage III colon cancer
The October 8 approvals cover adjuvant treatment of mismatch repair deficient colon cancer, with different age and weight limits for the two formulations.
What the record says
FDA approved intravenous Tecentriq with a fluoropyrimidine and oxaliplatin for adults and children age two and older with Stage III dMMR colon cancer. The subcutaneous Tecentriq Hybreza combination is approved for patients age 12 and older weighing at least 40 kilograms.
FDA approval date: October 8, 2026.
Both combinations concern Stage III mismatch repair deficient colon cancer.
Formulation-specific pediatric criteria differ.
Source details and supporting locations.
Practical next step
Patients and families can ask their oncology team whether the approved indication and formulation apply to their diagnosis and care plan.
Limits and what is not established
This is not approval for every type or stage of colon cancer. FDA notes immune-mediated and other serious risks. Individual eligibility, dosing and treatment decisions require the treating oncology team.
Sources checked October 11, 2026. Later notices may change instructions or arrangements.
Original sources
U.S. Food and Drug Administration: original information